🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
NCT06128148Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms
Guangzhou JOYO Pharma Co., Ltd
Phase 1
101
Guangzhou
2022-05-04
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Recruiting
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
NCT05644314Ischemic Stroke, Vertebral Artery Stenosis
Nanfang Hospital, Southern Medical University
Not applicable
144
Guangzhou
2022-05-01
Recruiting
Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC
NCT06002789Multiple Cancer, Colorectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
17
Guangzhou
2022-05-01
Recruiting
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
NCT05341492EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase EARLY_PHASE1
30
Guangzhou
2022-05-01
Active, closed
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05171647Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Recruiting
Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance
NCT05528783Colorectal Cancer
Sun Yat-sen University
Observational
200
Guangzhou
2022-04-25
Active, closed
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
NCT05319574Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University
Phase 2
46
Guangzhou
2022-04-24
Active, closed
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906Gaucher's Disease Type III
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Recruiting
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
NCT05342792Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
BeBetter Med Inc
Phase 2
200
Guangzhou, Changsha
2022-04-15
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Recruiting
Chronic Kidney Disease-related Sarcopenia With Poor Prognosis
NCT05353660Chronic Kidney Diseases, Sarcopenia
Nanfang Hospital, Southern Medical University
Observational
1,000
Guangzhou
2022-04-11
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Not yet open
Urinary Continence of Female POPRC and OIN
NCT05325216Urinary Bladder Neoplasms, Woman, Sexual Dysfunction, Physiological, Treatment Outcome
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
58
Guangzhou
2022-04
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Recruiting
Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam
NCT05160987Sedation and Analgesia
Zhujiang Hospital
Not applicable
440
Guangzhou
2022-03-29
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
Pfizer
Phase 3
854
Guangzhou, Tianjin, Wenzhou
2022-03-25
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
NCT05009069Rectal Neoplasms, Rectal Cancer
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Recruiting
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
NCT05367206Cervical Cancer, Neoadjuvant Chemotherapy, Bulky Neoplasm
Sun Yat-sen University
Phase 3
280
Guangzhou
2022-03-14
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Active, closed
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB
NCT06743438Hepatitis B, Chronic
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4
640
Guangzhou
2022-03-10
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids
NCT05694039Age-related Hearing Loss, Hearing Loss, Sensorineural, Hearing Aid, Cognitive Function Abnormal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
388
Guangzhou
2022-03-09
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Recruiting
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991Advanced Endometrial Cancer
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Recruiting
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT05435248Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2
354
Guangzhou
2022-03-02
Recruiting
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
NCT05228431Advanced Rectal Cancer
Zhen-Hai Lu
Phase 2
121
Guangzhou
2022-03-02
Recruiting
Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis
NCT05189496Radiation Pneumonitis
Guangdong Provincial People's Hospital
Not applicable
380
Guangzhou
2022-03-01
Recruiting
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
NCT05272696Head and Neck Squamous Cell Carcinoma
Guangdong Provincial People's Hospital
Phase 2
86
Guangzhou
2022-03-01
Not yet open
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Recruiting
Evaluation of Chronic Liver Disease Condition and Transplant Prognosis Assisted by Eye Biological Parameters
NCT06756009Diagnostic Techniques, Ophthalmological, Liver Transplantation, Liver Cirrhoses
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
500
Guangzhou
2022-03-01
Recruiting
THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein
NCT05194423Tricuspid Valve Regurgitation
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Active, closed
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
NCT05220267Non Clear Cell Renal Carcinoma
Sun Yat-sen University
Phase 2
44
Guangzhou
2022-02-28
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613Breast Cancer
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
NCT05285826Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Active, closed
Tumor-informed MRD for Non-small Cell Lung Cancer
NCT07596433Non-small Cell Lung Cancer (NSCLC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
450
Guangzhou
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
NCT04417166Lymphoma, Extranodal NK-T-Cell
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
30
Guangzhou, Shanghai
2022-02-11
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
NCT05104775Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691HER2-positive Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
By invitation
The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
NCT06851403Asthma in Children
Guangzhou Institute of Respiratory Disease
Observational
213
Guangzhou
2022-01-30
Recruiting
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
NCT06404164Pulmonary Function Assessment, Disease Free Survival, NSCLC, Stage I
Guangdong Provincial People's Hospital
Not applicable
3,000
Guangzhou
2022-01-30
Active, closed
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
NCT05353816End-stage Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Active, closed
Phase 3 Clinical Study of AK112 for NSCLC Patients
NCT05184712Non-Squamous Non-small Cell Lung Cancer
Akeso
Phase 3
322
Guangzhou
2022-01-25
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an
2022-01-24
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Active, closed
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05193617Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
104
Guangzhou
2022-01-20
Active, closed
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
NCT05198609Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Active, closed
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence
NCT06143644Colorectal Cancer
Sun Yat-sen University
Observational
220
Guangzhou
2022-01-15
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
NCT06618014Breast Cancer, Triple Negative Breast Cancer
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
NCT05182463Hepatitis B, Chronic
Third Affiliated Hospital, Sun Yat-Sen University
Phase 4
5,000
Guangzhou
2022-01-08
Recruiting
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
NCT04840264Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
79
Guangzhou
2022-01-07
Active, closed
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
NCT05003037Non Small Cell Lung Cancer
Li Zhang, MD
Phase 2
106
Guangzhou
2022-01-06
Active, closed
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Active, closed
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Recruiting
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
NCT07516678Neuroblastoma
Sun Yat-sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
NCT05468242Stage III Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2
116
Guangzhou
2022-01-01
Active, closed
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome
NCT05165069Hand-foot Syndrome
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
234
Guangzhou
2022-01-01
Recruiting
Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma
NCT06725576Thyroid Cancer, Papillary
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
201
Guangzhou
2022-01-01
Recruiting
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics
NCT05251883Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
NCT06760117Pediatric Solid Tumor
Sun Yat-sen University
Phase 1
39
Guangzhou
2022-01-01
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Phase 1
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
Recruiting
Multi-model Image of Doxycycline in TAO
NCT05112211Thyroid Associated Ophthalmopathy
Sun Yat-sen University
Not applicable
20
Guangzhou
2022-01-01
Recruiting
IBD Biomarker Discovery and Validation Platform
NCT07686406Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
6,000
Guangzhou
2022-01-01
Recruiting
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
NCT05450029Rectal Cancer
Yanhong Deng
Phase 2
51
Guangzhou
2022-01-01
By invitation
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866Rectal Cancer
Sun Yat-sen University
Observational
58
Guangzhou
2022-01-01
Recruiting
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
NCT05236972Colorectal Carcinoma
Sun Yat-sen University
Phase 3
323
Guangzhou
2022-01-01
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
By invitation
A Cohort Study on Cardiovascular and Cerebrovascular Outcomes
NCT07178015Stroke, Atheroscleroses
Sun Yat-sen University
Observational
855
Guangzhou
2021-12-30
Recruiting
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT05170503Esophagogastric Junction Adenocarcinoma
Sun Yat-sen University
Phase 2
37
Guangzhou
2021-12-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Recruiting
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
NCT05188885Chronic Kidney Disease
Guangdong Provincial People's Hospital
Observational
90,000
Foshan, Guangzhou, Meizhou, Qingyuan, Zhuhai, Ganzhou
2021-12-27
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Rows per page Showing 2701–2800 of 3318
Previous 26 27 28 29 30 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=28

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.